Medscape Medical News

Monoclonal antibody cendakimab also reduced eosinophils compared with placebo

Dupilumab demonstrated real-world efficacy in patients with severe, treatment-refractory fibrostenotic eosinophilic esophagitis, most of whom would not have qualified for prior clinical trials.

The ulcerative colitis drug etrasimod appeared to be efficacious in eosinophilic esophagitis, with notable reductions seen in eosinophils.

One year after therapy, higher sputum IgE was among the measures associated with remission.

Asthma control scores improved significantly over a 2.5-year period of continuous benralizumab therapy.

Measuring esophageal distensibility can help define the severity of early scarring in the esophagus of children with eosinophilic esophagitis and guide care.

In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.

The results add to 'current understanding of the role of different biomarkers in treatment response,' in this population, according to the lead study author.

IL-5 inhibitors lead to dramatic reductions in eosinophil levels within 3 days in five patients with drug reaction with eosinophilia and systemic symptoms (DRESS).

Data from a meta-analysis suggest that patients with low eosinophil counts derive little benefit from these therapies.

Benralizumab is a highly effective biologic for the management of severe eosinophil asthma.

Transcriptomic profiles showed mainly T2-low asthma endotypes in studies of primarily minority children.

Benralizumab led to histologic remission for patients with eosinophilic gastritis, but persistent symptoms point to involvement of eosinophil-independent disease mechanisms.

Severe asthma requires a multidisciplinary approach that involves treatment with multiple drugs at high doses, according to pulmonologists.

Patients with asthma are regularly seen by primary care providers (PCPs), but a survey found that 82% of PCPs do not order labs, and 90% do not use absolute eosinophil counts to guide care.

The drug received FDA approval for EoE treatment earlier this year.

Results of a randomized trial suggest that blood eosinophil-directed prednisolone can be an option to reduce glucocorticoid use in COPD patients.

Chronic pruritus of unknown origin becomes more common as people get older and is sometimes debilitating, according to Shawn Kwatra, MD.

Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs.